home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

233 rows where filing_period = "fourth_quarter", filing_year = 2014 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 233 ✖

filing_year 1

  • 2014 · 233 ✖

filing_period 1

  • fourth_quarter · 233 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1615911 SLC HEALTH STRATEGIES, LLC b9060d1e-336f-46e3-bec2-9051451ef90c 4T SLC HEALTH STRATEGIES, LLC 401018877 CUBIST PHARMACEUTICALS, INC. 2014 fourth_quarter PHA Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013 H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort HOUSE OF REPRESENTATIVES,SENATE 60000   0 1 2014-12-29T13:05:39.897000-05:00
1616400 MR. THEODORE (TED) JONES 508db430-b25f-4c5e-b3c9-a160ea494ee0 Q4 MR. THEODORE (TED) JONES 20926 COQUI RADIOPHARMACEUTICALS, CORP. 2014 fourth_quarter PHA American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013. Acceleration of production on 99 MO using LEU (Low Enriched Uranium). HOUSE OF REPRESENTATIVES,SENATE 93397   0 0 2015-01-05T12:53:43.150000-05:00
1616739 AMERICAN COLLEGE OF CLINICAL PHARMACY a01f11d3-8d91-4c00-8063-0f0110829195 Q4 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2014 fourth_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   124015 0 0 2015-01-07T09:55:01.333000-05:00
1616946 PD FRAZER CONSULTING, INC. 284a3926-41a8-4364-b938-e61f680be019 Q4 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2014 fourth_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-01-08T09:01:53.723000-05:00
1617462 MR. VINCENT A. PANVINI 3f4003a1-c277-42cc-bcc1-e98cfaf9df4a Q4 MR. VINCENT A. PANVINI 401008845 PHRMA 2014 fourth_quarter PHA Trans-Pacific Partnership HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-09T12:44:01.983000-05:00
1617611 PARRY, ROMANI, DECONCINI & SYMMS 14cb42c4-23a0-4eb0-b0c1-e61d774f69f4 Q4 PARRY, ROMANI, DECONCINI & SYMMS 30792 POZEN, INC. 2014 fourth_quarter PHA Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. HOUSE OF REPRESENTATIVES,SENATE 36000   0 0 2015-01-09T15:04:52.773000-05:00
1618191 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE dee9afe1-d91d-49f4-8e0e-8650f0491be5 Q4 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2014 fourth_quarter PHA Poll Results Regarding Use of Biosimilar Drugs HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2015-01-12T13:35:15.187000-05:00
1618336 THORSEN FRENCH ADVOCACY LLC 23cc5495-0f1b-4d88-b129-8252a31a007c Q4 THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2014 fourth_quarter PHA Issues related to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-12T15:11:33.637000-05:00
1618909 UNIVERSITY OF IOWA 0beb9a1f-e75f-442f-8d51-44e8c65b9941 Q4 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2014 fourth_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   85562 0 0 2015-01-13T12:21:55.823000-05:00
1619112 ROCK & ASSOCIATES d3bd786c-6ca6-4af6-93e2-d215b3d67923 Q4 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T14:14:55.113000-05:00
1619142 ROCK & ASSOCIATES 0fe3045e-c6b1-45df-9a18-f4c0178b6a5f Q4 ROCK & ASSOCIATES 33545 CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-13T14:23:08.407000-05:00
1619171 ROCK & ASSOCIATES 8a4f77f8-2c49-4192-a939-9a0f5d30ff68 Q4 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T14:30:19.253000-05:00
1619195 ROCK & ASSOCIATES 84e0c4bc-6433-4966-a744-6c35f5f7b0a0 Q4 ROCK & ASSOCIATES 33545 TOWN & COUNTRY COMPOUNDING AND CONSULTING 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T14:38:34.393000-05:00
1619224 ROCK & ASSOCIATES b71066b9-f9b8-48a1-9635-a328b029a285 Q4 ROCK & ASSOCIATES 33545 US COMPOUNDING 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T14:47:48.737000-05:00
1619263 ROCK & ASSOCIATES 4608612f-1c91-4f95-b8a2-f1ed7a7b094d Q4 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T14:57:05.423000-05:00
1619292 ROCK & ASSOCIATES 6498f44c-7b15-4368-bbf4-6cf5c61370c8 Q4 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T15:03:20.033000-05:00
1619308 ROCK & ASSOCIATES 050cec62-546e-4f6e-bfde-d6104bf5693d Q4 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2014 fourth_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-01-13T15:08:29.690000-05:00
1619778 CHRISTY ELLERBEE CONSULTING, LLC 5e328b70-f723-45eb-bfb4-bcb3941071d1 Q4 CHRISTY ELLERBEE CONSULTING, LLC 401103332 INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) 2014 fourth_quarter PHA Pharmaceutical issues relevant to Reckitt Benckiser Pharmaceuticals, Inc. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-14T10:08:31.050000-05:00
1619842 NAHIGIAN STRATEGIES, LLC 60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f Q4 NAHIGIAN STRATEGIES, LLC 322897 TEVA PHARMACEUTICALS USA INC 2014 fourth_quarter PHA Issues related to generic drug exclusivity. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2015-01-14T10:29:03.693000-05:00
1620257 THE MADISON GROUP 5b65e5bf-140a-4dbe-91a6-a64eeec2894a Q4 THE MADISON GROUP 284050 WEST-WARD PHARMACEUTICALS 2014 fourth_quarter PHA Issues pertaining to generic pharmaceutical drugs. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-14T12:43:19.897000-05:00
1620320 ABRAHAM & ROETZEL, LLC ac47f9c6-f234-4947-9189-b964509e551f Q4 ABRAHAM & ROETZEL, LLC 400954757 MATCHRX 2014 fourth_quarter PHA Implementation of Drug Quality and Security Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-14T13:24:44.553000-05:00
1620358 NOVO NORDISK INC. e925438f-51ad-429c-b964-4470e280660d Q4 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2014 fourth_quarter PHA HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA)   280000 0 0 2015-01-14T13:41:50.507000-05:00
1620545 RED+BLUE STRATEGIES d60147b9-1b09-45c9-9ae3-4accc61d20a2 Q4 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2014 fourth_quarter PHA H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. Issues regarding prescription drug coverage for the Department of Defense. Issues related to Part D coverage for Medicare Beneficiaries in Hospice Care. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-01-14T14:33:09.270000-05:00
1620693 KATE MOSS d8db3f71-5d6a-4d32-9bc8-0ca3d05b9d53 Q4 KATE MOSS 25988 CVS HEALTH 2014 fourth_quarter PHA Issues related to prescription drug abuse and drug supply chain safety. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-01-14T15:17:03.897000-05:00
1620813 VENABLE LLP d6dedd52-f975-44d3-b5a4-0543a412d98c Q4 VENABLE LLP 39941 ENDO PHARMACEUTICALS INC 2014 fourth_quarter PHA Issues related to tamper resistant formulation of pharmaceutical drugs. The Life Sciences Jobs and Investment Act HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-14T15:57:16.553000-05:00
1621081 RED+BLUE STRATEGIES 452d88df-c419-40c8-8f8d-cf439c05097c Q4 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2014 fourth_quarter PHA Implementation and rulemaking related to the Physician Payment Sunshine Act - A Medicare-related provision in the Health Reform Law focused on increasing systemic transparency. H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - ensuring that the pipeline for antibiotics is developed in the country. The Senate PATH Act of 2014 - focused on ensuring that the pipeline for antibiotics is developed in the country. Issues related to curbing prescription drug abuse and diversion. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-14T17:48:54.697000-05:00
1621139 INDEPENDENT PHARMACY COOPERATIVE 409f71c5-8075-4d81-8cde-0efe678dd0c7 Q4 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2014 fourth_quarter PHA Medicaid pharmacy reimbursement National Average Acquisition Cost(NADAC)-Clarify provisions and methodology Drug Quality and Security Act-Implementation deadline Restricted pharmacy networks in Medicare Part D-Oppose Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-14T18:49:16.493000-05:00
1621146 RED+BLUE STRATEGIES 136ed1a1-f2d3-43b5-91d2-25a2757942a9 4A RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2014 fourth_quarter PHA Issues related to the 21st Century Cures legislative efforts CCIIO issuer letter and regulations focused on bids for 2015 and its impact on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks. Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits. Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order. Issues related to the practice of providing coupons for prescription medications for seniors. Issues related to access to prescription drugs for Medicare beneficiaries in Hospice. Issues related to specialty pharmacy. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-01-14T19:12:23.100000-05:00
1621149 RUBICON ADVISORS, LLC f1f46d50-256e-4872-91c3-8cf9e612aa73 Q4 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2014 fourth_quarter PHA 21st Century Cures Act   105000   0 0 2015-01-14T19:24:27.177000-05:00
1621152 RUBICON ADVISORS, LLC 4d6a4e8d-ed64-455b-bc72-255bf5a1a529 Q4 RUBICON ADVISORS, LLC 315091 OFFICE OF GOVERNOR NATHAN DEAL 2014 fourth_quarter PHA Medicare/Medicaid HOUSE OF REPRESENTATIVES,SENATE 43750   0 0 2015-01-14T19:28:29.413000-05:00
1621153 RUBICON ADVISORS, LLC e12981a4-19a2-4996-9184-8fb0763430f1 Q4 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2014 fourth_quarter PHA Food and Drug Administration - Vaccines HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-14T19:30:30.380000-05:00
1621154 RUBICON ADVISORS, LLC 4d9d26c2-1508-43cc-8935-b08afd719bf6 Q4 RUBICON ADVISORS, LLC 315091 STATE MUTUAL INSURANCE COMPANY 2014 fourth_quarter PHA Pharmacy - Compounding HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-01-14T19:34:31.380000-05:00
1621156 RUBICON ADVISORS, LLC 5e93fb76-13eb-4c3f-aeeb-8220bcf4f58d Q4 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2014 fourth_quarter PHA Prescription Drug Abuse Policy HOUSE OF REPRESENTATIVES,SENATE 52500   0 0 2015-01-14T19:38:33.537000-05:00
1621159 RUBICON ADVISORS, LLC dce775a8-9683-4034-b584-0f174fbce422 Q4 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2014 fourth_quarter PHA Physician Payment rates, Electronic Health Records Incentives Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-14T19:47:35.880000-05:00
1621166 RUBICON ADVISORS, LLC 7d75c19d-2ce7-48d9-ac25-0252d23688a0 Q4 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2014 fourth_quarter PHA Food and Drug Administration, Generic Drug User Fees HOUSE OF REPRESENTATIVES,SENATE 36000   0 0 2015-01-14T19:51:39.207000-05:00
1621749 WILLIAMS AND JENSEN, PLLC cc3335a2-fbe7-4b1b-9120-2da59a8b9c65 Q4 WILLIAMS AND JENSEN, PLLC 41454 UNITED COMPOUNDING MANAGEMENT, LLC 2014 fourth_quarter PHA The compounded drug benefit under the TRICARE program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-15T11:19:41.613000-05:00
1621802 WILLIAMS AND JENSEN, PLLC b506d632-b813-4f34-aed9-806d2ad2e1f8 4T WILLIAMS AND JENSEN, PLLC 41454 PHARMACY SERVICES 2014 fourth_quarter PHA Regulations of compounding pharmacies. HOUSE OF REPRESENTATIVES,SENATE     0 1 2015-01-15T11:31:46.660000-05:00
1622164 CHAMBER HILL STRATEGIES 35152e9e-7f41-4d46-9885-d78fdcfac117 Q4 CHAMBER HILL STRATEGIES 400645947 AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) 2014 fourth_quarter PHA Implementation issues related to P.L. 113-54, the Drug Quality and Security Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-01-15T13:01:38.520000-05:00
1622254 TCH GROUP, LLC 50dde04b-3307-473d-963d-7efedd60eac0 Q4 TCH GROUP, LLC 51478 SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC ) 2014 fourth_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-01-15T13:24:21.417000-05:00
1622539 ACADEMY OF MANAGED CARE PHARMACY 7aa72339-46d4-4ba7-9e2f-184052752de6 Q4 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2014 fourth_quarter PHA Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528) Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   228000 0 0 2015-01-15T14:53:54.387000-05:00
1623647 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) d3b74d5a-c6cf-46d4-b618-ac6ae208389e Q4 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2014 fourth_quarter PHA Issues related to pharmaceutical pricing, safety, and FDA oversight. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   466000 0 0 2015-01-16T09:18:15.880000-05:00
1623768 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 5748e2b8-7695-4733-add0-e39eb247e854 Q4 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2014 fourth_quarter PHA Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs; Prescription Drug Abuse - General issues related to Rx drug abuse, (S. 348, S. 1277, H.R. 4069, H.R. 4709, S. 2862), Hydrocodone Rescheduling (H.R. 1285, S. 621); Counterfeit Drugs; Importation of Prescription Drugs Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   257000 0 0 2015-01-16T09:55:38.690000-05:00
1623844 EMPIRE CONSULTING GROUP 712ed119-5837-4efb-9ddd-4e63749f4837 Q4 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2014 fourth_quarter PHA Issues relating to the Medicare Prescription Drug Act; 340B Drug Pricing Program and drug pricing generally; health disparities in diverse communities. HOUSE OF REPRESENTATIVES 40000   0 0 2015-01-16T10:15:21.113000-05:00
1623883 ANIMAL HEALTH INSTITUTE 6eade180-b0a2-487a-8fae-9ea2cb834874 Q4 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2014 fourth_quarter PHA FDA approval process; illegal drug manufacturing under the guise of compounding HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2015-01-16T10:23:17.597000-05:00
1624148 SCONSET STRATEGIES, LLC 47401657-1545-4247-baca-df9d7e1bcfc2 Q4 SCONSET STRATEGIES, LLC 400794388 FREEMAN ALLERGY, INC. 2014 fourth_quarter PHA Issues related to securing additional clinical trials nationally and internationally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-16T11:07:55.173000-05:00
1624150 CROSSROADS STRATEGIES, LLC 9af09abb-ed74-4cc4-aa13-5bbccd7aa319 4T CROSSROADS STRATEGIES, LLC 400531586 LUMARA HEALTH 2014 fourth_quarter PHA Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 60000   0 1 2015-01-16T11:08:06.767000-05:00
1624370 KOUNTOUPES DENHAM CARR & REID, LLC bd795afe-f531-41d9-86c8-c875a8588e80 Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2014 fourth_quarter PHA General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014. Issues related to pediatric flow restrictors; Issues related to Energy and Commerce draft of "21st Century Cures." Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2015-01-16T11:33:54.533000-05:00
1624870 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f0c8f135-b0b6-4103-8fb3-77efd0505f3c Q4 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2014 fourth_quarter PHA HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1989 Cancer Treatment Parity Act. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2015-01-16T12:56:00.547000-05:00
1624998 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 09fa5301-e986-43c9-a11c-5918675ccc43 Q4 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2014 fourth_quarter PHA Issues related to anti-epileptic drugs Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2015-01-16T13:14:23.967000-05:00
1625025 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 34ec78c8-53fc-4bc0-90cb-1952590e022a Q4 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2014 fourth_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 460 Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2015-01-16T13:22:35.060000-05:00
1625054 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 3374c419-46ec-4241-8f9f-922ee32ed9a3 Q4 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2014 fourth_quarter PHA issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-16T13:28:46.767000-05:00
1625094 NELSON MULLINS RILEY & SCARBOROUGH 517ad289-02f8-4564-9ce2-08a90e28424c Q4 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2014 fourth_quarter PHA Any legislation and regulation to the treatment of opioid abuse HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-16T13:35:04.920000-05:00
1625146 SANOFI US SERVICES INC. 176f7748-4e29-4284-b466-54290f8df198 Q4 SANOFI US SERVICES INC. 56838 SANOFI US SERVICES INC 2014 fourth_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE   840000 0 0 2015-01-16T13:42:56.520000-05:00
1625483 RED+BLUE STRATEGIES 35d599ca-3168-4a96-bacd-224b25cb1869 Q4 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2014 fourth_quarter PHA Issues related to curbing opioid abuse in the United States. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-01-16T14:23:41.797000-05:00
1625680 RED+BLUE STRATEGIES 9af7f844-81da-4542-8b0e-d87c3f6b76e9 Q4 RED+BLUE STRATEGIES 400693064 HOSPIRA 2014 fourth_quarter PHA Issues related to creating a new marketplace for biosimilar medications in the United States. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS) 30000   0 0 2015-01-16T14:43:52.953000-05:00
1626220 BLUECROSS BLUESHIELD OF TENNESSEE 2f295214-9fd2-45de-bcc7-7a10b09cc9e7 Q4 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2014 fourth_quarter PHA General Pharmacy Issues; specialty drug pricing. HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2015-01-16T15:39:10.260000-05:00
1626351 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING b7ed1477-db90-46de-9cc4-93eb549dbc20 Q4 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2014 fourth_quarter PHA Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204). Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   90000 0 0 2015-01-16T15:56:01.213000-05:00
1627216 CAPITOL HILL CONSULTING GROUP 73a19823-3bb8-4c46-94be-8f90721db3c7 Q4 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2014 fourth_quarter PHA Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R.486) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-01-16T20:16:10.867000-05:00
1627533 ENDO INTERNATIONAL ce846f4e-c380-45fa-943e-901383d29882 Q4 ENDO INTERNATIONAL 40011075 ENDO INTERNATIONAL 2014 fourth_quarter PHA Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act. HOUSE OF REPRESENTATIVES,SENATE   540000 0 0 2015-01-17T14:33:35.900000-05:00
1627578 THE D MAJOR GROUP 942ac07a-4784-457e-9ab0-e50a09cf625d Q4 THE D MAJOR GROUP 401103162 HEALTH CARE SUPPLY CHAIN ASSOCIATION 2014 fourth_quarter PHA Issues related to the implementation of the Drug Quality and Supply Act. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-01-17T15:44:55.597000-05:00
1627598 THE D MAJOR GROUP b6df8468-c5cd-408c-bddc-b7c02b15566d Q4 THE D MAJOR GROUP 401103162 CVS CAREMARK 2014 fourth_quarter PHA Issues concerning prescription drug abuse related to H.R. 3392, the "Medicare Part D Patient Safety & Drug Abuse Prevention Act;" H.R. 4069, the "Ensuring Patient Access & Effective Drug Enforcement Act of 2014;" and Protecting Integrity in Medicare Act (discussion draft). HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-17T16:07:05.247000-05:00
1627613 THE D MAJOR GROUP b31b6746-24a7-4e68-ba84-b84577045cd3 4A THE D MAJOR GROUP 401103162 HEALTH CARE SUPPLY CHAIN ASSOCIATION 2014 fourth_quarter PHA Issues related to the implementation of the Drug Quality and Supply Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-17T16:14:07.727000-05:00
1627731 CAPITOL HILL CONSULTING GROUP 1709e62f-3c2b-4f06-990e-8f9c04388864 Q4 CAPITOL HILL CONSULTING GROUP 72053 ENDO PHARMACEUTICALS 2014 fourth_quarter PHA Ensuring Safe Access to Prescription Medication Act of 2014 S.2825 HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-01-17T21:57:12.187000-05:00
1627918 OMNICARE, INC. d85711df-e6dc-4658-8079-64abf4e1d571 Q4 OMNICARE, INC. 321112 OMNICARE INC 2014 fourth_quarter PHA Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities; Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs; Controlled substances policy; Biosimilars policy; Hazardous drug handling policy     20000 0 0 2015-01-18T13:12:34.250000-05:00
1628084 SHIRE PHARMACEUTICALS LLC 08775d50-846b-4794-a047-d4fd98aef239 Q4 SHIRE PHARMACEUTICALS LLC 323477 SHIRE PHARMACEUTICALS LLC 2014 fourth_quarter PHA issues surrounding ADHD, including economic and social impact; binge eating disorder; drug shortages; DEA processes; FDA funding and sequester; specialty tiers; track and trace; step therapy; drug development; patent issues; H.R. 5805, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access; H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2014; Priority Review Vouchers; FDASIA implementation; ACA implementation; bundling rules for the Hospital Outpatient Prospective Payment System; CMS coding coverage; line extension rebates; Medicare Part D rebates; H.J. Res. 59, Continuing Appropriations Resolution, 2014 and possible drug industry issues; tax reform; orphan drug tax credit; R&D tax credits Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   380000 0 0 2015-01-18T14:23:31.687000-05:00
1628229 CAPITOL HILL CONSULTING GROUP e1bfcabf-7936-4269-bcdb-09419f471d6a Q4 CAPITOL HILL CONSULTING GROUP 72053 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2014 fourth_quarter PHA Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 2015 National Defense Authorization Act Issues related to implementation of the Compounding Quality Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-01-18T15:59:32.933000-05:00
1628350 HEARTLAND SOLUTIONS GROUP, INC. ca0a5771-3f49-4f65-8c58-382d3005909f Q4 HEARTLAND SOLUTIONS GROUP, INC. 312133 ZEBRA TECHNOLOGIES CORPORATION 2014 fourth_quarter PHA Any and all issues related to labeling of generic drugs. HOUSE OF REPRESENTATIVES,SENATE 9000   0 0 2015-01-18T19:12:28.557000-05:00
1628423 ALKERMES, INC. d2cc3339-6ff9-4a7b-9224-beefb886c1d0 Q4 ALKERMES, INC. 400458235 ALKERMES, INC. 2014 fourth_quarter PHA DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   965000 0 0 2015-01-18T21:22:18.750000-05:00
1628439 CAPITOL HILL CONSULTING GROUP 5be00e79-ab92-4d0e-a203-d00baab3fe77 Q4 CAPITOL HILL CONSULTING GROUP 72053 WELLNESS PHARMACY 2014 fourth_quarter PHA Pharmaceutical Compounding and Accountability Act S.959 The Compound Clarity Act H.R.3089 The Drug Quality and Security Act H.R.3204 Issues related to implementation of the Compounding Quality Act HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-01-18T21:53:20.120000-05:00
1628448 CAPITOL HILL CONSULTING GROUP 2e0868c9-765b-4dac-b354-1136f39bd820 Q4 CAPITOL HILL CONSULTING GROUP 72053 BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS 2014 fourth_quarter PHA issues related to, but not limited to, pharmacy HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-18T22:04:22.337000-05:00
1629003 EISAI INC. 794fd321-6fed-40ec-835e-39890a672aec Q4 EISAI INC. 400321512 EISAI INC. 2014 fourth_quarter PHA DEA Scheduling of Controlled Substances H.R. 4299 -- Improving Regulatory Transparency for New Medical Therapies Act S. 2862 -- Transparency, Patient Access and Effective Drug Enforcement Act of 2014 HOUSE OF REPRESENTATIVES,SENATE   500000 0 0 2015-01-19T11:13:31.920000-05:00
1629241 GOLDEN HORIZONS 3562bb51-ad06-43fc-8ecf-cdd4e10bfd2e Q4 GOLDEN HORIZONS 44275 GOLDEN HORIZONS 2014 fourth_quarter PHA Monitor and advocate regarding pharmacy issues impacting Long Term Care and Post Acute Care providers and patients. Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),SENATE,Veterans Affairs, Dept of (VA)   95997 0 0 2015-01-19T12:34:48.797000-05:00
1629295 VALENTE & ASSOCIATES 98a79f81-acfc-4390-b692-73882095cacb Q4 VALENTE & ASSOCIATES 45983 SAV-MOR FRANCHISING, INC. 2014 fourth_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES 30000   0 0 2015-01-19T12:45:35.703000-05:00
1629370 PRIME THERAPEUTICS 57c2c74e-392d-4013-8b23-f68a44c5b05c Q4 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2014 fourth_quarter PHA Prescription Drug Abuse. Support of the Alliance to Prevent the Abuse of Medicines legislative priorities including minimum requirements for state databases, pharmacy lock-in programs, and abuse deterrent technology. Biosimilars - concerns regarding naming (shared names with reference product vs. original names); specialty drug cost trends HR 4577 Ensuring Seniors Access to Local Pharmacies Act - opposed HR 460 Patients Access to Treatment Act - opposed HR 4437 Medication Therapy Empowerment Act - oppose expanding to one condition Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   250000 0 0 2015-01-19T13:02:02.017000-05:00
1629482 SQUIRE PATTON BOGGS 6537eba1-2dac-4af8-a0fd-2f77ab27b44c Q4 SQUIRE PATTON BOGGS 30906 HEMISPHERX BIOPHARMA, INC. 2014 fourth_quarter PHA Ebola response legislation and regulatory actions. Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-19T13:35:59.657000-05:00
1629563 WHITMER & WORRALL, LLC f8d1da23-4be3-47e9-966d-ac4696598447 Q4 WHITMER & WORRALL, LLC 292892 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2014 fourth_quarter PHA Issues related to The Patient Protection and Affordable Care Act (Public Law 111 148) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-19T13:51:09.453000-05:00
1629698 MASON CONSULTING, LLC e1bba96a-b613-41f9-ac22-785d15cbdb3b Q4 MASON CONSULTING, LLC 400660986 NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS 2014 fourth_quarter PHA Legislation and policies relating to: FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug H.R. 1919 - Safeguarding Americas Pharmaceuticals Act S. 621 - Safe Prescribing Act S. 959 - Pharmaceutical Compounding Quality and Accountability Act H.R. 3089 - Compounding Clarity Act H.R. 3204 - Drug Quality and Security Act (Public Law 113-54) H.R 4069 - Ensuring Patient Access and Effective Drug Enforcement Act Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office 23450   0 0 2015-01-19T14:22:58.060000-05:00
1630071 SLC HEALTH STRATEGIES, LLC cca30f28-2661-4fac-8737-fd9a745cfed9 Q4 SLC HEALTH STRATEGIES, LLC 401018877 EISAI INC. 2014 fourth_quarter PHA Obesity product matters as well as FDA funding HR 4299 --Improving Regulatory Transparency for New Medical Therapies Act re: DEA scheduling of controlled substances S. 2862 - Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 re: DEA scheduling of controlled substances HOUSE OF REPRESENTATIVES,SENATE 40500   0 0 2015-01-19T15:22:19.437000-05:00
1630083 SLC HEALTH STRATEGIES, LLC 33121b0e-fa6f-4106-872c-460146204877 Q4 SLC HEALTH STRATEGIES, LLC 401018877 NOVO NORDISK PHARMACEUTICALS, INC. 2014 fourth_quarter PHA FDA issues regarding biosimilar products; 340B program matters HOUSE OF REPRESENTATIVES,SENATE 27000   0 0 2015-01-19T15:24:25.563000-05:00
1630089 MCKENNA, LONG & ALDRIDGE 1dcc2ed9-c94f-4001-b4cc-6fbf9c66cfc7 Q4 MCKENNA, LONG & ALDRIDGE 76913 PURDUE PHARMA 2014 fourth_quarter PHA U.S. and Canadian regulatory policies regarding prescription drug abuse. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-01-19T15:25:34.920000-05:00
1630232 BLUESTONE STRATEGIES, LLC 5b574e22-4f00-4f99-a114-a3c351efad24 Q4 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2014 fourth_quarter PHA Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-01-19T15:46:14.717000-05:00
1630938 NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC 657ce517-b15b-497f-87e3-8dffc01846ad Q4 NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC 400689052 WOCKHARDT USA LLC 2014 fourth_quarter PHA Issues related to preemption for ANDA labels and FDA rule HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-19T18:33:42.080000-05:00
1631021 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 79a5a7fa-97c0-4018-8603-697521b65eb1 Q4 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2014 fourth_quarter PHA No issues this period. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Personnel Management (OPM),SENATE     0 0 2015-01-19T19:28:04.750000-05:00
1631230 GREENBERG TRAURIG, LLP 26753888-be01-48e9-afa5-2f02e1a7ff39 Q4 GREENBERG TRAURIG, LLP 16896 VERIMED, LLC 2014 fourth_quarter PHA Monitor legislative and administrative action regarding prescription drug abuse and diversion policies. Monitor passage and implementation of Consolidated and Further Continuing Appropriations Act, 2015 (P.L. 113-235). Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 60000   0 0 2015-01-19T21:44:09.470000-05:00
1631241 CAPITOL COUNSEL LLC a99acb1b-4260-4a9f-b0ee-0fc1db249aaf Q4 CAPITOL COUNSEL LLC 313715 AMERICAN HEALTH CARE ASSOCIATION 2014 fourth_quarter PHA S.1560: Nursing Home Resident Pain Relief Act of 2011. S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012. S.621: Safe Prescribing Act. Continued monitoring of Nurse Agent and Drug disposal issue Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2015-01-19T21:48:04.517000-05:00
1631346 THE WALTER GROUP c6a39f28-967a-4757-ab26-c4bf8034cba2 Q4 THE WALTER GROUP 309537 AMERISOURCEBERGEN 2014 fourth_quarter PHA H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-01-19T22:34:10.173000-05:00
1631660 GREATER NEW YORK HOSPITAL ASSOCIATION a6bf12a2-5e47-4818-adba-df6ca46fdcb8 Q4 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2014 fourth_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; opposing the current HRSA guidance on the 340b drug pricing GPO exclusion (HRSA Release 2013-1); opposing taxes on mobile health applications (FDA mobile health guidance and regulatory risk-based framework, FDA-2011-D-0530, FDA-2014-N-0339); comments on regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.5435) - support; comments on Medicare physician services pertaining to non-face-to-face chronic care management services (CMS-1612-P); reforming the durable medical equipment competitive bidding program; and hospice medication coverage reforms. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,White House Office   290000 0 0 2015-01-20T08:36:37.703000-05:00
1631905 NOSSAMAN LLP 5189c4c7-0809-4340-9bd6-749a5aa2b71f Q4 NOSSAMAN LLP 29846 AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP") 2014 fourth_quarter PHA H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959) HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-01-20T09:24:38.203000-05:00
1632113 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 8b01b843-3f7e-471a-94c9-8e5a09a9faa3 Q4 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 401103386 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2014 fourth_quarter PHA Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825) HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2015-01-20T09:38:09.343000-05:00
1632288 MEHLMAN CONSULTING, INC. 05680a7a-8299-4205-8821-e2008fe07bd0 Q4 MEHLMAN CONSULTING, INC. 284950 WALMART INC 2014 fourth_quarter PHA Discussion on implementation of Medicare Part D and the Affordable Care Act. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2015-01-20T09:56:23.490000-05:00
1632442 BRAVO GROUP 04d5c53f-17c1-4458-8e84-8f907005650a Q4 BRAVO GROUP 296293 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2014 fourth_quarter PHA Biopharmaceutical issues including: social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-01-20T10:06:40.333000-05:00
1632486 ASSOCIATION OF NATIONAL ADVERTISERS, INC. ef53be4c-2e14-4e18-8178-c6849cd42fa8 Q4 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2014 fourth_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising FDA studies relating to direct to consumer prescription drug advertising Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE   360000 0 0 2015-01-20T10:09:51.320000-05:00
1632518 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2d24cd01-57eb-4714-b182-a6d6b2bf7cff Q4 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2014 fourth_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). H.R. 4502 - Stop Meth Labs and Enhance Patient Access Act of 2014 (all sections). Would grant additional authority to the Drug Enforcement Administration (DEA) to grant exemptions to the provisions of the Combat Methamphetamine Epidemic Act of 2005 (P.L. 109-177). Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R. 4250/S. 2141 - Sunscreen Innovation Act. Would require FDA to approve or deny new sunscreen ingredient applications under the "time and extent" application (TEA) process within a certain timeframe after submission; all sections. HOUSE OF REPRESENTATIVES,SENATE   230000 0 0 2015-01-20T10:10:56.817000-05:00
1632798 THE UNITED STATES PHARMACOPEIAL CONVENTION 2b5232f6-ce00-43cc-9721-b8872cf7ccda Q4 THE UNITED STATES PHARMACOPEIAL CONVENTION 400358632 THE UNITED STATES PHARMACOPEIAL CONVENTION 2014 fourth_quarter PHA Advise on standards-setting, verification, overseas programs and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients. Implementation of Public Law: 113-54.; Drug Quality and Security Act; provisions related to compounding standards. HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2015-01-20T10:30:53.723000-05:00
1632920 AVENUE SOLUTIONS 8d49ad52-9038-483b-ac17-b8d1e2b25483 Q4 AVENUE SOLUTIONS 72111 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 2014 fourth_quarter PHA Issues relating to biosimilars SENATE 30000   0 0 2015-01-20T10:39:36.583000-05:00
1633021 AVENUE SOLUTIONS 42b895c0-ebcc-4ef2-a9ee-0c16ae63f462 Q4 AVENUE SOLUTIONS 72111 MOMENTA PHARMACEUTICALS, INC. 2014 fourth_quarter PHA Issues relating to biogenerics and Medicare reimbursement   50000   0 0 2015-01-20T10:43:01.457000-05:00
1633104 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6095c419-c761-4d8c-9c9e-619abbabcf83 Q4 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2014 fourth_quarter PHA No issues this period Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   2030000 0 0 2015-01-20T10:46:26.863000-05:00
1633437 KOUNTOUPES DENHAM CARR & REID, LLC e63b55ce-f601-4e4e-a4c1-06ab63eabf6e Q4 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2014 fourth_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, e-labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program as well as issues related to Energy and Commerce Committee's draft on 21st Century Cures. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 50000   0 0 2015-01-20T11:06:21.050000-05:00
1633747 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 4d7f10dd-e7e2-464d-ae9e-5b353890ae1b Q4 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2014 fourth_quarter PHA H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; S. 557 Medication Therapy Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; H.R..3979 Carl Levin and Howard P. Buck Mckeon National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); Prescription Drug Abuse and Diversion; H.R. Res. 130-FY 2015 Continuing Resolution (though December 14, 2014); H.J. Res. 291- Making Further Continuing Appropriations for Fiscal Year 2015, And For Other Purposes (Until December 17, 2014); H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act; H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act of 2014; Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE   420000 0 0 2015-01-20T11:27:05.317000-05:00
1633869 BUCHANAN INGERSOLL & ROONEY PC acd656ff-2b94-4304-a753-3995a74e9f6b Q4 BUCHANAN INGERSOLL & ROONEY PC 55291 PENNSYLVANIA BIOTECHNOLOGY ASSOCIATION - ALA: PENNSYLVANIA BIO 2014 fourth_quarter PHA Life sciences, orphan drugs HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-01-20T11:33:45.377000-05:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 3994.832ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API